Skip to main content

Table 1 Demographics by group

From: Real-world use of difelikefalin in hemodialysis patients at a large dialysis organization in the United States: a retrospective database study

Characteristic

All Patients

(N = 715)

CRG

(N = 295)

IRG

(N = 420)

Baseline (pre-DFK) WI-NRS score, mean (SD)

8.5 (1.7)

8.5 (1.8)

8.5 (1.6)

12-week WI-NRS score available, n (%)

156 (21.8)

84 (28.5)

72 (17.1)

DFK dose, mL, mean (SD)a

0.81 (0.24)

0.83 (0.25)

0.79 (0.24)

Female, n (%)

345 (48.3)

124 (42.0)

221 (52.6)

Black, n (%)

285 (39.9)

113 (38.3)

172 (41.0)

Hispanic, n (%)

68 (9.5)

29 (9.8)

39 (9.3)

Age at first DFK administration, years, mean (SD)

64.7 (13.0)

66.1 (12.9)

63.8 (13.1)

Vintage at first DFK administration, years, mean (SD)

4.8 (4.5)

4.4 (4.2)

5.2 (4.6)

Primary insurance, n (%)

   

 Medicare

319 (44.6)

129 (43.7)

190 (45.2)

 Commercial

5 (0.7)

2 (0.7)

3 (0.7)

 Managed Medicare

388 (54.3)

162 (54.9)

226 (53.8)

 Exchange

2 (0.3)

1 (0.3)

1 (0.2)

 Self

1 (0.1)

1 (0.3)

0 (0.0)

  1. aSupplied as 50 µg/mL. CRG, complete regimen group; IRG, incomplete regimen group; DFK, difelikefalin; WI-NRS, Worst Itching Intensity Numerical Rating Scale; SD, standard deviation